Bofanglutide (GZR18)
GZR18 · Gan & Lee Pharmaceuticals
GLP-1 injection with biweekly induction studies and a separate monthly maintenance study.
Selected study results
GRADUAL-1 · ChinaMean body-weight change from baselineBody weight decreased 18.54% · 52 weeks · Phase 3
Mean body-weight change from baseline · 52 weeks
Study focus: Weight management
Sponsor topline; Phase 3 China result, with a separate U.S. Phase 2 program.
Adults with overweight or obesity in China · 48 mg every two weeks vs placebo · Trial N=640 · Modified intention-to-treat; sponsor topline. Results & methods ↗
Not a head-to-head comparison with other programs. Gastrointestinal events were generally mild to moderate; no new safety signal was reported.
U.S. Phase 2 · primary analysisMean body-weight change from baselineBody weight decreased 13.99% · 36 weeks · Phase 2
Mean body-weight change from baseline · 36 weeks
Study focus: Weight management without type 2 diabetes
Randomized U.S. Phase 2 trial: three bofanglutide regimens, placebo and an open-label tirzepatide arm.
Adults with overweight or obesity without type 2 diabetes · 48 mg every two weeks · Trial N=325 · Full analysis set; primary treatment-regimen estimand. Results & methods ↗
| Regimen | Mean weight reduction |
|---|---|
| Bofanglutide 24 mg every two weeks | 13.35% |
| Bofanglutide 36 mg every two weeks | 13.24% |
| Bofanglutide 48 mg every two weeks | 13.99% |
| Placebo | 0.84% |
- Separate per-protocol analysis · same trialThe 48-mg group had 15.18% mean weight loss at week 36 in the earlier sponsor per-protocol report. This exploratory analysis differs from the full-analysis-set treatment-regimen estimates above. Follow-up source ↗
No dose-equivalence or superiority conclusion versus tirzepatide is established here. Gastrointestinal adverse events were the most common, generally mild to moderate. China GRADUAL-1 and monthly maintenance are separate studies.
GRADUAL-3 · monthly maintenanceMean body-weight change from maintenance baselineBody weight decreased 0.12% · 24-week maintenance period · Phase 3b
Mean body-weight change from maintenance baseline · 24-week maintenance period
Study focus: Weight-loss maintenance
Eligible Chinese GRADUAL-1 completers after 52 weeks of biweekly bofanglutide · 24 or 48 mg once monthly after biweekly induction · N not included in this summary · Sponsor topline; analysis population and estimand not disclosed. Results & methods ↗
| Monthly regimen | Weight change |
|---|---|
| 24 mg | +0.41% |
| 48 mg | −0.12% |
| Placebo | +8.52% |
- 24 mg monthlyMean weight change was +0.41% versus +8.52% with placebo. Both active-dose comparisons had P<0.0001 in the sponsor topline.
Selected completers entered a separate maintenance period. Values start at maintenance baseline, not original induction baseline. Arm sizes, confidence intervals, estimand and numerical discontinuation rates were not disclosed; full publication is pending.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Safety context
The sponsor described gastrointestinal events as generally mild to moderate, with no new safety signal in the reported studies.
Mechanism at a glance
Obesity stage by formulation
Latest: Gan & Lee reported GRADUAL-3 monthly maintenance topline results on November 4, 2026, following 52 weeks of biweekly treatment in GRADUAL-1.
Next: Full GRADUAL-3 results and peer-reviewed reports; further regional development updates.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
GRADUAL-1 · China · NCT06728124
Weight managementChina GRADUAL-1 completed March 26, 2026, with 640 actual participants (registry update posted November 12). The registry lists the primary weight endpoint at week 48; the separate sponsor topline reports 52-week results. Preserve those source-specific timepoints. No registry results are posted.
GRADUAL-3 · monthly maintenance
Weight-loss maintenanceRandomized 24-week monthly maintenance after 52 weeks of biweekly bofanglutide in eligible GRADUAL-1 completers; 24 mg or 48 mg versus placebo. Separate from induction.
Phase 2 studies1 record
U.S. Phase 2 · NCT06737042
Weight management325 participants randomized and treated: bofanglutide 24, 36 or 48 mg every two weeks, placebo, or open-label tirzepatide 15 mg weekly. Week-36 primary analysis uses the full analysis set and treatment-regimen estimand.
